Literature DB >> 32885958

Synergistic Local Combination of Radiation and Anti-Programmed Death Ligand 1 Immunotherapy Using Radiation-Responsive Splintery Metallic Nanocarriers.

Bongseo Choi1, Hyunjun Choi1,2, Bo Yu1, Dong-Hyun Kim1,2,3,4.   

Abstract

Radiation therapy (RT)-mediated tumor immunogenicity offers an opportunity for synergistic combination RT and immunotherapy. One of the challenges in the clinic is to attain the optimum efficacy of combination RT and immunotherapy with minimized overlapping toxicities. Here, to achieve synergistic therapeutic efficacy of combinational RT and anti-programmed death ligand 1 (aPD-L1) immunotherapy, RT-responsive splintery snowflake-like Au nanocarriers (S-AuNC) were synthesized with a method for hierarchical bimetallic supra-nanostructures. Primary Au nanocrystals interconnected with Ag nanocrystals in S-AuNC showed RT-responsive structural deformation resulting in RT-triggered release of cargo aPD-LI in S-AuNC. The local combination of RT and aPD-L1 loaded S-AuNC significantly enhanced the immunogenic cell death for tumor microenvironment conversion. RT-triggered local aPD-L1 release allowed a controlled spatiotemporal combination RT and aPD-L1 immunotherapy resulting in a synergistic anticancer adaptive immune response with minimized systemic immune-related adverse effects.

Entities:  

Keywords:  gold nanocarrier; image-guided cancer therapy; immune-related adverse events; immunotherapy; localized cancer therapy; radiotherapy

Mesh:

Substances:

Year:  2020        PMID: 32885958     DOI: 10.1021/acsnano.0c04701

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  8 in total

1.  Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy.

Authors:  Bongseo Choi; Dong-Hyun Kim
Journal:  Adv Nanobiomed Res       Date:  2021-08-02

Review 2.  Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.

Authors:  Kwang-Soo Kim; Dong-Hwan Kim; Dong-Hyun Kim
Journal:  Pharmaceutics       Date:  2021-04-09       Impact factor: 6.321

Review 3.  Immunogenic Cell Death Induction by Ionizing Radiation.

Authors:  Mengqin Zhu; Mengdie Yang; Jiajia Zhang; Yuzhen Yin; Xin Fan; Yu Zhang; Shanshan Qin; Han Zhang; Fei Yu
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

Review 4.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

5.  Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.

Authors:  Yuanming Li; Runqi Guo
Journal:  J Oncol       Date:  2022-03-15       Impact factor: 4.375

Review 6.  Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy.

Authors:  Jin Zhang; Yandai Lin; Zhe Lin; Qi Wei; Jiaqi Qian; Renjie Ruan; Xiancai Jiang; Linxi Hou; Jibin Song; Jianxun Ding; Huanghao Yang
Journal:  Adv Sci (Weinh)       Date:  2021-12-19       Impact factor: 16.806

Review 7.  Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes.

Authors:  Yang Xuan; Meng Guan; Shubiao Zhang
Journal:  Theranostics       Date:  2021-05-25       Impact factor: 11.556

Review 8.  Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.

Authors:  Pratibha Pandey; Fahad Khan; Huda A Qari; Tarun Kumar Upadhyay; Abdulhameed F Alkhateeb; Mohammad Oves
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.